Methods of treating an overweight subject
US-2015335608-A1 · Nov 26, 2015 · US
Methods of treating age related disorders
US9446016B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9446016-B2 |
| Application number | US-201414244278-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 3, 2014 |
| Priority date | Oct 3, 2011 |
| Publication date | Sep 20, 2016 |
| Grant date | Sep 20, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an oxidative stress disorder in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a MetAP2 inhibitor selected from O-(4-dimethylaminoethoxycinnamoyl)fumagillol and pharmaceutically acceptable salts thereof, wherein the oxidative stress disorder is sarcopenia. 2. The method of claim 1 , wherein said patient exhibits a reduction in expression of mCLK1. 3. The method of claim 1 , wherein the patient, upon administration of the MetAP2 inhibitor, exhibits a decrease in non-mitochondrial oxidative damage. 4. The method of claim 1 , wherein the patient, upon administration of the MetAP2 inhibitor, exhibits increased mitochondrial oxidative stress. 5. The method of claim 1 , wherein said therapeutically effective amount does not substantially modulate or suppress angiogenesis. 6. The method of claim 1 , further comprising administration of the MetAP2 inhibitor until a marker level is returned to a normal range. 7. The method of claim 6 , wherein the marker is C-reactive protein. 8. The method of claim 1 , wherein said MetAP2 inhibitor is administered parenterally or non-parenterally. 9. The method of claim 1 , wherein the MetAP-2 inhibitor is administered at a dose of about 0.01 mg/kg to about 10 mg/kg. 10. The method of claim 1 , wherein the MetAP-2 inhibitor is administered at a dose of about 0.04 mg/kg to about 1.0 mg/kg.
Assignees
Inventors
Classifications
General protective or antinoxious agents · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Free radical scavengers or antioxidants · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anorexiants; Antiobesity agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9446016B2 cover?
- The invention generally relates to methods of treating a patient having, and/or at risk of, oxidative distress disorders and/or age-related disorders. The disclosure also generally relates to methods of treating memory impairment or enhancing the cognitive function of a patient in need thereof. Such methods may include administering a therapeutically effective amount of a MetAP2 inhibitor.
- Who is the assignee on this patent?
- Zafgen Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/336. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Sep 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 7 related publications on this page (citations in our corpus or others sharing the same primary CPC).